Campbell & Co Investment Adviser’s 10x Genomics TXG Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.93M	Buy	+102,568	New	+$2.69M	0.21%	129

Other funds holding TXG

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return

Financial Consulate Hunt Valley, Maryland $899M AUM 20.23% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

Campbell & Co Investment Adviser's TXG Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in 10x Genomics (TXG) in Q2 2026: 102,568 shares worth $3.93M. The stake represents 0.21% of the portfolio and ranks #129 among its holdings.

114 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Campbell & Co Investment Adviser held 102,568 shares of 10x Genomics worth $3.93M as of Q2 2026.
10x Genomics was a new Campbell & Co Investment Adviser position in Q2 2026.
10x Genomics made up 0.21% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #129 holding.
114 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.